Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Surface Oncology, Inc. from 31 Dec 2016 to 30 Jun 2023

Taxonomy & unit: us-gaap: USD
Description: Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary: Surface Oncology, Inc. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 31 Dec 2016 to 30 Jun 2023.
Surface Oncology, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Jun 2023 was $27,844,000, a 9.3% decline year-over-year.
Surface Oncology, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 30 Jun 2023 was $91,556,000, a 43% decline year-over-year.
Surface Oncology, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $64,380,000, a 18% increase from 2021.
Surface Oncology, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was $78,706,000, a 233% decline from 2020.
Surface Oncology, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was $59,234,000.
Source SEC data: View on sec.gov

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Surface Oncology, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2023	$91,556,000	$27,844,000	-$2,372,000	-9.3%	01 Apr 2023	30 Jun 2023	10-Q	02 Aug 2023	2023	Q2
Q1 2023	$89,184,000	$19,295,000	-$24,804,000	-450%	01 Jan 2023	31 Mar 2023	10-Q	04 May 2023	2023	Q1
Q4 2022	$64,380,000	$20,978,000	+$3,290,000	+14%	01 Oct 2022	31 Dec 2022	8-K	03 Jul 2023		Q4
Q3 2022	$67,670,000	$23,439,000	-$3,552,000	-18%	01 Jul 2022	30 Sep 2022	10-Q	02 Nov 2022	2022	Q3
Q2 2022	$64,118,000	$25,472,000	-$6,483,000	-34%	01 Apr 2022	30 Jun 2022	10-Q	02 Aug 2023	2023	Q2
Q1 2022	$57,635,000	$5,509,000	+$21,071,000		01 Jan 2022	31 Mar 2022	10-Q	04 May 2023	2023	Q1
Q4 2021	$78,706,000	$24,268,000	-$91,612,000	-136%	01 Oct 2021	31 Dec 2021	8-K	03 Jul 2023		Q4
Q3 2021	$12,906,000	$19,887,000	-$4,063,000	-26%	01 Jul 2021	30 Sep 2021	10-Q	02 Nov 2022	2022	Q3
Q2 2021	$16,969,000	$18,989,000	-$4,066,000	-27%	01 Apr 2021	30 Jun 2021	10-Q	03 Aug 2022	2022	Q2
Q1 2021	$21,035,000	$15,562,000	-$38,199,000	-169%	01 Jan 2021	31 Mar 2021	10-Q	09 May 2022	2022	Q1
Q4 2020	$59,234,000	$67,344,000	+$83,333,000		01 Oct 2020	31 Dec 2020	8-K	03 Jul 2023		Q4
Q3 2020	$24,099,000	$15,824,000	+$1,090,000	+6.4%	01 Jul 2020	30 Sep 2020	10-Q	04 Nov 2021	2021	Q3
Q2 2020	$25,189,000	$14,923,000	+$2,666,000	+15%	01 Apr 2020	30 Jun 2020	10-Q	05 Aug 2021	2021	Q2
Q1 2020	$27,855,000	$22,637,000	+$26,712,000		01 Jan 2020	31 Mar 2020	10-Q	05 May 2021	2021	Q1
Q4 2019	$54,567,000	$15,989,000	-$11,325,000	-243%	01 Oct 2019	31 Dec 2019	10-K	02 Mar 2022	2021	Q4
Q3 2019	$43,242,000	$16,914,000	+$265,000	+1.5%	01 Jul 2019	30 Sep 2019	10-Q	10 Nov 2020	2020	Q3
Q2 2019	$43,507,000	$17,589,000	-$1,800,000	-11%	01 Apr 2019	30 Jun 2019	10-Q	11 Aug 2020	2020	Q2
Q1 2019	$41,707,000	$4,075,000	-$35,237,000	-113%	01 Jan 2019	31 Mar 2019	10-Q	12 May 2020	2020	Q1
Q4 2018	$6,470,000	$4,664,000	+$11,178,000	+71%	01 Oct 2018	31 Dec 2018	10-K	09 Mar 2021	2020	Q4
Q3 2018	$17,648,000	$17,179,000	-$2,817,000	-20%	01 Jul 2018	30 Sep 2018	10-Q	12 Nov 2019	2019	Q3
Q2 2018	$14,831,000	$15,789,000	-$9,256,000	-142%	01 Apr 2018	30 Jun 2018	10-Q	07 Aug 2019	2019	Q2
Q1 2018	$5,575,000	$31,162,000	+$39,695,000		01 Jan 2018	31 Mar 2018	10-Q	09 May 2019	2019	Q1
Q4 2017	$45,270,000	$15,842,000			01 Oct 2017	31 Dec 2017	10-K	10 Mar 2020	2019	Q4
Q3 2017		$14,362,000			01 Jul 2017	30 Sep 2017	10-Q	13 Nov 2018	2018	Q3
Q2 2017		$6,533,000			01 Apr 2017	30 Jun 2017	10-Q	14 Aug 2018	2018	Q2
Q1 2017		$8,533,000			01 Jan 2017	31 Mar 2017	10-Q	29 May 2018	2018	Q1

Surface Oncology, Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2022	$64,380,000	+$14,326,000	+18%	01 Jan 2022	31 Dec 2022	8-K	03 Jul 2023
2021	$78,706,000	-$137,940,000	-233%	01 Jan 2021	31 Dec 2021	8-K	03 Jul 2023
2020	$59,234,000	+$113,801,000		01 Jan 2020	31 Dec 2020	8-K	03 Jul 2023
2019	$54,567,000	-$48,097,000	-743%	01 Jan 2019	31 Dec 2019	10-K	02 Mar 2022	2021	FY
2018	$6,470,000	+$38,800,000	+86%	01 Jan 2018	31 Dec 2018	10-K	09 Mar 2021	2020	FY
2017	$45,270,000	-$27,464,000	-154%	01 Jan 2017	31 Dec 2017	10-K	10 Mar 2020	2019	FY
2016	$17,806,000			01 Jan 2016	31 Dec 2016	10-K	07 Mar 2019	2018	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.